Business Description
Theraclion
ISIN : FR0010120402
Total Employee Number:
33Compare
Compare
Traded in other countries / regions
ALTHE.France941.GermanyTCLIF.USA IPO Date
2026-04-23Description
Theraclion specializes in developing, manufacturing, and marketing echotherapy equipment, associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules. Its products include Sonovein, Echopulse, and Epack.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.68 | |||||
Equity-to-Asset | -0.17 | |||||
Debt-to-Equity | -1.91 | |||||
Debt-to-EBITDA | -0.97 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.07 | |||||
Beneish M-Score | 1.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -20.6 | |||||
3-Year EBITDA Growth Rate | 22.2 | |||||
3-Year EPS without NRI Growth Rate | 17.6 | |||||
3-Year FCF Growth Rate | 11.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.15 | |||||
9-Day RSI | 32.52 | |||||
14-Day RSI | 38.74 | |||||
3-1 Month Momentum % | 35.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.55 | |||||
Quick Ratio | 1.94 | |||||
Cash Ratio | 0.8 | |||||
Days Inventory | 205.02 | |||||
Days Sales Outstanding | 79.09 | |||||
Days Payable | 122.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -26.8 | |||||
Shareholder Yield % | -7.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -240.81 | |||||
Operating Margin % | -537.86 | |||||
Net Margin % | -479.76 | |||||
EBITDA Margin % | -428.75 | |||||
FCF Margin % | -621.42 | |||||
OCF Margin % | -603.63 | |||||
ROA % | -45.03 | |||||
ROIC % | -69.11 | |||||
3-Year ROIIC % | -40.67 | |||||
ROC (Joel Greenblatt) % | -348.12 | |||||
ROCE % | -85.02 | |||||
Moat Score | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 24.18 | |||||
EV-to-EBIT | -6.91 | |||||
EV-to-EBITDA | -8.66 | |||||
EV-to-Revenue | 37.13 | |||||
EV-to-FCF | -6.09 | |||||
Price-to-GF-Value | 2.26 | |||||
Price-to-Median-PS-Value | 2.17 | |||||
Earnings Yield (Greenblatt) % | -14.46 | |||||
FCF Yield % | -17.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Theraclion Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.186 | ||
| EPS (TTM) (€) | -0.106 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 38.74 | ||
| 14-Day ATR (€) | 0.019624 | ||
| 20-Day SMA (€) | 0.5996 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 0.436 - 0.93 | ||
| Shares Outstanding (Mil) | 73.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Theraclion Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Theraclion Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Theraclion Frequently Asked Questions
What is Theraclion(FRA:941)'s stock price today?
The current price of FRA:941 is €0.54. The 52 week high of FRA:941 is €0.93 and 52 week low is €0.44.
When is next earnings date of Theraclion(FRA:941)?
The next earnings date of Theraclion(FRA:941) is .
Does Theraclion(FRA:941) pay dividends? If so, how much?
Theraclion(FRA:941) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Theraclion
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers